Search Result

Results for "

Sacituzumab

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (2) ADC Payload (2) Antibody-Drug Conjugates (ADCs) (4) Autophagy (2) Biochemical Assay Reagents (1) Drug Metabolite (2) Drug-Linker Conjugates for ADC (3) Radionuclide-Drug Conjugates (RDCs) (1) Reference Standards (1) Topoisomerase (2) TROP2 (5)
By Research Areas:	Cancer (12)

Inhibitors & Agonists

Fluorescent Dyes

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13704

SN-38 65+ Cited Publications 7-Ethyl-10-hydroxycamptothecin	Drug Metabolite Topoisomerase ADC Payload Autophagy	Cancer
SN-38 is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 inhibits DNA and RNA synthesis with IC₅₀s of 0.077 and 1.3 μM, respectively. SN-38 is a payload of sacituzumab govitecan (HY -132254) .

HY-P99045

*Sacituzumab* 4 Publications Verification HRS7; hRS7	ADC Antibody TROP2	Cancer
Sacituzumab is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer .

HY-132254

Sacituzumab govitecan 5+ Cited Publications IMMU-132	Antibody-Drug Conjugates (ADCs) TROP2	Cancer
Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. The antibody portion is Sacituzumab (HY-P99045), and the drug-linker conjugate for ADC is CL2A-SN-38 (HY-128946). Sacituzumab govitecan shows anticancer activity .

HY-132254A

Sacituzumab govitecan (solution) 5+ Cited Publications IMMU-132 (solution)	Antibody-Drug Conjugates (ADCs) TROP2	Cancer
Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. The antibody portion is Sacituzumab (HY-P99045), and the drug-linker conjugate for ADC is CL2A-SN-38 (HY-128946). Sacituzumab govitecan shows anticancer activity .

HY-164789

Sacituzumab tirumotecan SKB264; MK-2870	Antibody-Drug Conjugates (ADCs) TROP2	Cancer
Sacituzumab tirumotecan is an antibody-drug conjugate and TROP2-directed, topoisomerase I inhibitor payload-delivering agent, with a TROP2 EC₅₀ of 2.787 ng/ml, TROP2 K_a of 0.3083 nM, and topoisomerase I IC₅₀ of 0.7 μmol/L. Sacituzumab tirumotecan can be used for the research of metastatic triple-negative breast cancer, and metastatic non-small cell lung cancer .

HY-P99045A

Sacituzumab (powder)	ADC Antibody TROP2	Cancer
Sacituzumab (powder) is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab (powder) demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab (powder) can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer .

HY-147340

TL033 Tirumotecan	Drug-Linker Conjugates for ADC	Cancer
TL033 is a drug-Linker conjugates for ADC. TL033 contains a linker and bioactive small molecule toxins. TL033 can conjugate with Sacituzumab antibody (anti Trop-2) for synthesizing BT001021. BT001021 has anti-cancer activities against various cancers, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer .

HY-147340A

TL033 TFA Tirumotecan TFA	Drug-Linker Conjugates for ADC	Cancer
TL033 TFA is a drug-Linker conjugates for ADC. TL033 TFA contains a linker and bioactive small molecule toxins. TL033 TFA can conjugate with Sacituzumab antibody (anti Trop-2) for synthesizing BT001021. BT001021 has anti-cancer activities against various cancers, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer .

HY-13704R

SN-38 (Standard) 7-Ethyl-10-hydroxycamptothecin (Standard)	Drug Metabolite Reference Standards Topoisomerase ADC Payload Autophagy	Cancer
SN-38 (Standard) is the analytical standard of SN-38. This product is intended for research and analytical applications. SN-38 is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 inhibits DNA and RNA synthesis with IC50s of 0.077 and 1.3 μM, respectively. SN-38 is a payload of sacituzumab govitecan (HY -132254) .

HY-150362

ADC Control Human IgG1-tirumotecan	Antibody-Drug Conjugates (ADCs)	Cancer
ADC Control Human IgG1-tirumotecan is an antibody-drug conjugate (ADC). The antibody portion is Human IgG1 kappa, Isotype Control (HY-P99001), and the drug-linker conjugate for ADC is TL033 TFA (HY-147340A). ADC Control Human IgG1-tirumotecan can be as a control of Sacituzumab tirumotecan (HY-164789).

HY-156514

MC-GGFG-AM-(10NH2-11F-Camptothecin)	Drug-Linker Conjugates for ADC	Cancer
MC-GGFG-AM-(10NH2-11F-Camptothecin) is an antibody drug conjugates (ADC). MC-GGFG-AM-(10NH2-11F-Camptothecin) binds to the anti-TROp-2 antibody sacituzumab via a hydrolysable pH-sensitive linker and has anti-tumor activity. MC-GGFG-AM-(10NH2-11F-Camptothecin) can be used for cancer research .

HY-183600

SCN-PYTA	Radionuclide-Drug Conjugates (RDCs) Biochemical Assay Reagents	Cancer
SCN-PYTA is a bifunctional chelator for trivalent radiometals. After conjugation with monoclonal antibodies, SCN-PYTA forms a stable complex with ²²⁵Ac to achieve efficient radiolabeling. SCN-PYTA can be used in cancer research .

Cat. No.	Product Name	Type

HY-132254

Sacituzumab govitecan 5+ Cited Publications IMMU-132	Fluorescent Dyes
Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. The antibody portion is Sacituzumab (HY-P99045), and the drug-linker conjugate for ADC is CL2A-SN-38 (HY-128946). Sacituzumab govitecan shows anticancer activity .

HY-132254A

Sacituzumab govitecan (solution) 5+ Cited Publications IMMU-132 (solution)	Fluorescent Dyes
Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. The antibody portion is Sacituzumab (HY-P99045), and the drug-linker conjugate for ADC is CL2A-SN-38 (HY-128946). Sacituzumab govitecan shows anticancer activity .

HY-164789

Sacituzumab tirumotecan SKB264; MK-2870	Fluorescent Dyes
Sacituzumab tirumotecan is an antibody-drug conjugate and TROP2-directed, topoisomerase I inhibitor payload-delivering agent, with a TROP2 EC₅₀ of 2.787 ng/ml, TROP2 K_a of 0.3083 nM, and topoisomerase I IC₅₀ of 0.7 μmol/L. Sacituzumab tirumotecan can be used for the research of metastatic triple-negative breast cancer, and metastatic non-small cell lung cancer .

Sacituzumab tirumotecan

SKB264; MK-2870

Fluorescent Dyes

Sacituzumab tirumotecan is an antibody-drug conjugate and TROP2-directed, topoisomerase I inhibitor payload-delivering agent, with a TROP2 EC₅₀ of 2.787 ng/ml, TROP2 K_a of 0.3083 nM, and topoisomerase I IC₅₀ of 0.7 μmol/L. Sacituzumab tirumotecan can be used for the research of metastatic triple-negative breast cancer, and metastatic non-small cell lung cancer .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99045

*Sacituzumab* 4 Publications Verification HRS7; hRS7	ADC Antibody TROP2	Cancer
Sacituzumab is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer .

HY-P99045A

Sacituzumab (powder)	ADC Antibody TROP2	Cancer
Sacituzumab (powder) is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab (powder) demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab (powder) can be used for the synthesis of antibody-drug conjugates (ADC) drug Sacituzumab govitecan (HY-132254). Sacituzumab govitecan can be used in the field of triple-negative breast cancer .

SN-38 65+ Cited Publications 7-Ethyl-10-hydroxycamptothecin	Alkaloids Classification of Application Fields Labiatae Samanea saman (Jacq.) Merr. Quinoline Alkaloids Plants Disease Research Fields Source Classification Cancer	Drug Metabolite Topoisomerase ADC Payload Autophagy
SN-38 is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 inhibits DNA and RNA synthesis with IC₅₀s of 0.077 and 1.3 μM, respectively. SN-38 is a payload of sacituzumab govitecan (HY -132254) .

SN-38 (Standard) 7-Ethyl-10-hydroxycamptothecin (Standard)	Alkaloids Labiatae Samanea saman (Jacq.) Merr. Quinoline Alkaloids Plants Source Classification	Drug Metabolite Reference Standards Topoisomerase ADC Payload Autophagy
SN-38 (Standard) is the analytical standard of SN-38. This product is intended for research and analytical applications. SN-38 is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 inhibits DNA and RNA synthesis with IC50s of 0.077 and 1.3 μM, respectively. SN-38 is a payload of sacituzumab govitecan (HY -132254) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.

Sacituzumab

Inhibitors & Agonists

Fluorescent Dyes

Inhibitory Antibodies

NaturalProducts

Natural
Products